

Model-driven scheduling of a novel anti-cancer prodrug administered subcutaneously

Anne Rodallec¹, Randy Lee¹, Jingming Cao², Sophie Marolleau¹, Julien Nicolas^{2*}, Sébastien Benzekry^{1*}


¹COMPO Unit, Inria Sophia Antipolis-Méditerranée, Cancer Research Center of Marseille, Inserm UMR1068, CNRS UMR7258, Aix Marseille University UM105, Marseille, France

² Université Paris-Saclay, CNRS, Institut Galien Paris-Saclay, 91400 Orsay, France


MOTIVATIONS & OBJECTIVES

Chemotherapy is a cornerstone in the treatment of solid tumors but is associated with high toxicities and patient discomfort. New formulations with **improved pharmacokinetics** (PK) are being developed to **increase efficacy** and to **reduce toxicities**. These formulations present greater: exposure, tumor uptake, lipophilicity and maximum tolerated dose, creating opportunities for broader therapeutic index.

EXPERIMENTAL BACKGROUND




Pharmacokinetic and Pharmacodynamic data




RESULTS


Final structural PK/PD Model



In vivo results and Model Validation



Diagnostic plots for the training (A) and test (B) data set



ACKNOWLEDGMENTS

This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (Grant agreement No. 771829).